English
Back
Download
Log in to access Online Inquiry
Back to the Top

NEWS

Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening

Tuesday, 10th December at 8:00 am
HENDERSON, Nev., Dec. 10, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which shows that its Nu.Q® Cancer Test differentiated between malignant and benign pulmonary nodules, found by Low Dose CT (LDCT) scan, in patients suspected of lung cancer.

The 800-patient prospective study was led by Professor Jin-Shing Chen and his team at National Taiwan University Hospital.

Findings published in a paper that is currently undergoing peer review and accessible on MedRXIV, conclude that a panel of two Nu.Q® nucleosome quantification assays (H3.1 and H3K27Me3) showed a diagnostic sensitivity of 92% and a Positive Predictive Value of 89% in identifying cancerous nodules when used in combination with LDCT screening.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
Translate
Report
6815 Views
Comment
Sign in to post a comment
    Spread kindness and love. Life is short. Don’t let greed eat you.
    8979
    Followers
    54
    Following
    107K
    Visitors
    Follow
    Reassessing Chinese Assets
    Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.